Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIK2 | Q9H0K1 | 16/20 | 0.55 |
| ▸ | SIK3 | Q9Y2K2 | 9/20 | 0.44 |
| ▸ | SIK1 | P57059 | 8/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21593330 | 0.82 | SIK2 (0.58) | SIK2SIK3SIK1RIPK2ABL1 | |
| SCHEMBL24169269 | 0.82 | SIK2 (0.58) | SIK2SIK3SIK1RIPK2ABL1 | |
| SCHEMBL24169470 | 0.78 | SIK2 (0.54) | SIK2SIK3SIK1RIPK2ABL1 | |
| SCHEMBL30130914 | 0.77 | SIK2 (0.58) | SIK2SIK3SIK1RIPK2ABL1 | |
| SCHEMBL21593403 | 0.76 | SIK2 (0.50) | SIK2SIK3SIK1RIPK2ABL1 | |
| SCHEMBL26440604 | 0.76 | SIK2 (0.49) | SIK2SIK3SIK1RIPK2ABL1 | |
| SCHEMBL22491255 | 0.75 | TP53 (0.36) | SIK2 | |
| SCHEMBL22747322 | 0.75 | SIK2 (0.51) | SIK2SIK3SIK1RIPK2ABL1 | |
| SCHEMBL29677167 | 0.75 | SIK2 (0.41) | SIK2SIK3SIK1EGFRMEN1 | |
| SCHEMBL22491205 | 0.75 | SIK2 (0.41) | SIK2SIK3SIK1EGFRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606554-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | ONCO3R THERAPEUTICS BV (BE) | 2026-04-21 | — | — | US | disclosed |
| US-20220235048-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-07-28 | — | — | US | disclosed |
| WO-2020239660-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235048-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | IL1A, IFNG, COL1A1 | SIK2 4505/4885SIK3 3536/4885SIK1 4093/4885 |
| US-12606554-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | IL23R, IL2, IL36G | SIK2 3971/4885SIK3 3243/4885SIK1 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.